Barclays Downgrades Abbott Labs (ABT) to Equalweight
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Price: $111.25 -0.02%
Rating Summary:
26 Buy, 9 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
26 Buy, 9 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays downgraded Abbott Labs (NYSE: ABT) from Overweight to Equalweight, price target maintained at $55.00.
Barclays analyst says, "...we see little potential for upside/downside movement near term." FY11 EPS cut $0.01 to $4.65 and FY12 raised $0.02 to $5.01.
For an analyst ratings summary and ratings history on Abbott Labs click here. For more ratings news on Abbott Labs click here.
Shares of Abbott Labs closed at $54.18 yesterday.
Barclays analyst says, "...we see little potential for upside/downside movement near term." FY11 EPS cut $0.01 to $4.65 and FY12 raised $0.02 to $5.01.
For an analyst ratings summary and ratings history on Abbott Labs click here. For more ratings news on Abbott Labs click here.
Shares of Abbott Labs closed at $54.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Abbott Labs (ABT) to Outperform
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- RBC Capital Downgrades CareTrust REIT (CTRE) to Sector Perform
Create E-mail Alert Related Categories
DowngradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
